BPC-157 dosage in animal and human studies
A number loses its meaning when the animal, injury and route are cropped away. The studies give experimental amounts; a personal regimen remains unestablished.
BPC-157 amounts in rat tendon and ulcer studies
The transected Achilles tendon experiment studied 10 microg, 10 ng or 10 pg per rat, with intraperitoneal and local administration. The gastric-ulcer experiment studied 400 ng/kg and 800 ng/kg in Wistar rats, using intramuscular and intragastric administration.
Per rat and per kilogram are not interchangeable. Nor are a cut tendon and an ulcer. A polished BPC-157 dosage chart troubles me when it removes those distinctions, even when every individual figure was copied correctly.
These amounts establish no safe or effective amount, treatment duration or cycle for people. The 2025 clinical-evidence review describes the missing rigorous human trials.
The route changes the question
BPC-157 injection research includes intraperitoneal administration into an animal's abdominal cavity, intramuscular administration and local delivery. Human pilot reports instead involved intravenous infusion, intravesical delivery into the bladder or intra-articular delivery into a knee joint. Each route addresses that study's question.
The intravenous safety pilot gave two healthy adults 10 mg on day 1 and 20 mg on day 2, with 1-hour infusions. The interstitial-cystitis pilot used a single 10 mg intravesical dose. These describe what investigators administered; human directions or a validated schedule remain unestablished.
For an illustration of why route alone is insufficient, the rat and dog pharmacokinetic study found different intramuscular bioavailability in the two species. The exposure comparison gives the figures without converting them into a human estimate.
Does oral BPC-157 work? Stability leaves that open
The stable-gastric-peptide description explains the interest in oral BPC-157. It does not establish how much reaches human blood. Formal human oral pharmacokinetics remain unestablished, and no controlled human trial here demonstrates oral efficacy.
In the rat ulcer comparison, intramuscular administration outperformed intragastric delivery. That result leaves me unconvinced that the stomach origin can do the work of an absorption study.
A short elimination half-life in rats and beagle dogs also cannot determine an oral human regimen, how quickly a person might feel a change, or how long use could safely continue. Those are separate unanswered questions.